Updates on Pharmacologic Management of Microvascular Angina

Mosayeb Soleymani1, Farzad Masoudkabir2,3, Mahsima Shabani4

  • 1Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Cardiovascular Therapeutics
|November 16, 2022
PubMed

Insights

Microvascular angina (MVA), a common cause of chest pain without blocked arteries, presents a treatment challenge. Beta-blockers and calcium channel blockers offer the most symptom relief for this condition.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Microvascular angina (MVA), also known as cardiac syndrome X, affects predominantly women with angina and nonobstructive coronary artery disease.
  • MVA poses a significant healthcare burden due to repeated diagnostic procedures and hospitalizations.
  • Current management strategies for MVA are limited, highlighting a gap in evidence-based guidelines.

Purpose of the Study:

  • To review the underlying mechanisms of MVA.
  • To summarize the outcomes of various pharmacologic interventions for MVA.
  • To provide an updated overview of MVA treatment options.

Main Methods:

  • Literature review of studies on MVA pathophysiology.
  • Analysis of clinical trial data on medications used for MVA.
  • Synthesis of current knowledge on pharmacologic management of MVA.

Main Results:

  • Nitrates are ineffective for MVA, unlike vasospastic angina.
  • Beta-blockers and calcium channel blockers demonstrate the strongest evidence for symptom improvement.
  • ACE inhibitors, ARBs, statins, estrogen, and novel antianginal drugs show promising results.
  • Emerging therapies like vitamin D, omega-3, incretins, and N-acetyl cysteine show initial benefits.

Conclusions:

  • Effective management of MVA requires further research and guideline development.
  • Integrating current and future trial results into cardiac care guidelines can reduce healthcare costs.
  • Pharmacologic interventions, particularly beta-blockers and calcium channel blockers, are key to managing MVA symptoms.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
15
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
32
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
623
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
695
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19